First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting
At this interim analysis, finerenone was initiated in patients with CKD and T2D across various clinical practices participating in the study. Treatment discontinuation and hyperkalemia occurred infrequently.
Authors
- Susanne B. Nicholas (ORCID: https://orcid.org/0000-0003-3535-9120)
- Alain Gay (ORCID: https://orcid.org/0000-0002-0689-7168)
- Antonio Garreta-Rufas
- Martin Merz
- Andrea Horvat-Broecker
- Stefanie Hamacher (ORCID: https://orcid.org/0000-0003-2158-9101)
- Samuel Fatoba
- Nihar R. Desai (ORCID: https://orcid.org/0000-0003-2384-2545)
- Ricardo Correa-Rotter
- Sankar Dass Navaneethan (ORCID: https://orcid.org/0000-0002-4953-7795)
- Kevin M. Pantalone (ORCID: https://orcid.org/0000-0002-3897-4551)
- Lixin Guo (ORCID: https://orcid.org/0000-0003-2596-8387)
- David C. Wheeler
- Christoph Wanner
Institutions
- Cleveland Clinic (US)
- Yale New Haven Hospital (US)
- Bayer (United States) (US)
- University of California, Los Angeles (US)
- Baylor College of Medicine (US)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Beijing Hospital (CN)
- Universitätsklinikum Würzburg (DE)
- University College London (GB)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Journal of Nephrology
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1007/s40620-024-02070-y
- Citations
- 16
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 5.72
Funders
- Bayer